In Austin, VC is booming for biotechs

Further evidence of Texas' growing power in the biotech industry: the Austin Business Journal reports that in recent months, central Texas-based life science outfits have attracted about $500 million in VC. "The 'we can't do bio in Austin' attitude is no longer true," said Isaac Barchas, director of the University of Texas' IC2 Institute. "Taken together, it feels like this is the moment when things are happening in bio. I think in two years we'd point to this moment and say, 'that was when things started to happen.'" Texas' biotech efforts--particularly its $3 billion bond program for cancer research--propelled it to first place on FierceBiotech's annual list of the top five regions attracting biotech business.

- see the Austin Business Journal piece
- read FierceBiotech's special report on Texas. Report

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.